{'52WeekChange': -0.54615384,
 'SandP52WeekChange': 0.0644362,
 'address1': '351 Galveston Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.2,
 'askSize': 3100,
 'averageDailyVolume10Day': 1884100,
 'averageVolume': 1235220,
 'averageVolume10days': 1884100,
 'beta': 1.810644,
 'beta3Year': None,
 'bid': 1.17,
 'bidSize': 1200,
 'bookValue': -0.687,
 'category': None,
 'circulatingSupply': None,
 'city': 'Redwood City',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.19,
 'dayLow': 1.07,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.345,
 'enterpriseToRevenue': 30.186,
 'enterpriseValue': 72749224,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 1.2302858,
 'fiftyTwoWeekHigh': 2.8,
 'fiftyTwoWeekLow': 0.7,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 79422265,
 'forwardEps': -0.28,
 'forwardPE': -4.2142854,
 'fromCurrency': None,
 'fullTimeEmployees': 59,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.018660001,
 'heldPercentInstitutions': 0.24014,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/acelrx.com',
 'longBusinessSummary': 'AcelRx Pharmaceuticals, Inc., a specialty '
                        'pharmaceutical company, focuses on the development '
                        'and commercialization of therapies for the treatment '
                        "of acute pain. The company's lead product candidate "
                        'is DSUVIA, a 30 mcg sufentanil sublingual tablet for '
                        'the treatment of moderate-to-severe acute pain. It '
                        'also develops ZALVISO, a pre-programmed and '
                        'patient-controlled analgesia system that allows '
                        'hospital patients with moderate-to-severe acute pain '
                        'to self-dose with sufentanil sublingual tablets to '
                        'manage their pain. The company was formerly known as '
                        'SuRx Pharmaceuticals, Inc. and changed its name to '
                        'AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx '
                        'Pharmaceuticals, Inc. was founded in 2005 and is '
                        'headquartered in Redwood City, California.',
 'longName': 'AcelRx Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 95301280,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_33172220',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -55491000,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.13,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650-216-3500',
 'previousClose': 1.12,
 'priceHint': 4,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 39.544098,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.19,
 'regularMarketDayLow': 1.07,
 'regularMarketOpen': 1.13,
 'regularMarketPreviousClose': 1.12,
 'regularMarketPrice': 1.13,
 'regularMarketVolume': 1357039,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 80763800,
 'sharesPercentSharesOut': 0.1398,
 'sharesShort': 11287404,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 8990632,
 'shortName': 'AcelRx Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.1418,
 'shortRatio': 9.49,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'ACRX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.698,
 'twoHundredDayAverage': 1.402446,
 'volume': 1357039,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.acelrx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94063'}